ELANCO ANIMAL HEALTH INC (ELAN) Forecast, Price Target & Analyst Ratings
NYSE:ELAN • US28414H1032
23.92 USD
-0.52 (-2.13%)
At close: Mar 5, 2026
23.92 USD
0 (0%)
After Hours: 3/5/2026, 8:04:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ELANCO ANIMAL HEALTH INC (ELAN).
Forecast Snapshot
Consensus Price Target
$27.20
+ 13.71% Upside
Next Earnings Forecast
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate$0.35
Revenue Estimate1.316B
ChartMill Buy Consensus
85.45%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$27.20
Upside
+ 13.71%
From current price of $23.92 to mean target of $27.20, Based on 22 analyst forecasts
Low
$22.22
Median
$27.54
High
$31.50
Price Target Revisions
1 Month
4.42%
3 Months
11.11%
Price Target Summary
22 analysts have analysed ELAN and the average price target is 27.2 USD. This implies a price increase of 13.71% is expected in the next year compared to the current price of 23.92.
The average price target has been revised upward by 11.11% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.45%
ELAN was analyzed by 22 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about ELAN.
In the previous month the buy percentage consensus was at a similar level.
ELAN was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-25 | Keybanc | Maintains | Overweight -> Overweight |
| 2026-02-25 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-24 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2026-02-19 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-01-22 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2025-12-18 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-11-21 | Keybanc | Initiate | Overweight |
| 2025-11-06 | UBS | Maintains | Buy -> Buy |
| 2025-10-20 | UBS | Maintains | Buy -> Buy |
| 2025-10-07 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2025-09-24 | Stifel | Maintains | Buy -> Buy |
| 2025-08-11 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-08-08 | UBS | Maintains | Buy -> Buy |
| 2025-07-23 | UBS | Maintains | Buy -> Buy |
| 2025-07-17 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-07-02 | Stifel | Maintains | Buy -> Buy |
| 2025-06-26 | William Blair | Upgrade | Market Perform -> Outperform |
| 2025-05-19 | Stifel | Maintains | Buy -> Buy |
| 2025-05-08 | Stifel | Maintains | Buy -> Buy |
| 2025-04-14 | Stifel | Maintains | Buy -> Buy |
| 2025-03-06 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-02-26 | UBS | Maintains | Buy -> Buy |
| 2025-02-26 | Stifel | Maintains | Buy -> Buy |
| 2025-02-26 | Barclays | Maintains | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate$0.35
Revenue Estimate1.316B
Revenue Q2Q10.31%
EPS Q2Q-4.68%
Number of Analysts15
Next Earnings Revisions
Revenue (1 Month)
0.09%
Revenue (3 Months)
0.09%
EPS (1 Month)
0.00%
EPS (3 Months)
-2.19%
Next Earnings Summary
ELAN is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is 0.35 USD and the consensus revenue estimate is 1.32B USD.
The next earnings revenue estimate has been revised upward by 0.09% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.417B 0.14% | 4.439B 0.50% | 4.715B 6.22% | 5.091B 7.97% | 5.356B 5.21% | 5.608B 4.71% | 5.853B 4.37% | 6.037B 3.14% | 6.206B 2.80% | 6.377B 2.76% | 6.428B 0.80% | |
| EBITDA YoY % growth | 1.02B -4.32% | 913M -10.49% | 932M 2.08% | 1.001B 7.40% | 1.092B 9.09% | 1.194B 9.34% | 1.266B 6.03% | 1.33B 5.06% | 1.389B 4.44% | 1.467B 5.62% | 1.454B -0.89% | |
| EBIT YoY % growth | 326M -15.10% | 251M -23.01% | 252M 0.40% | 777.95M 208.71% | 866.22M 11.35% | 1.029B 18.79% | 1.105B 7.39% | 1.163B 5.25% | 1.217B 4.64% | 1.289B 5.92% | 1.262B -2.09% | |
| Operating Margin | 7.38% | 5.65% | 5.34% | 15.28% | 16.17% | 18.35% | 18.88% | 19.26% | 19.61% | 20.21% | 19.63% | |
| EPS YoY % growth | 0.89 -19.82% | 0.91 2.25% | 0.95 4.40% | 1.05 10.73% | 1.18 12.42% | 1.34 13.21% | 1.51 12.57% | 1.54 2.20% | 1.63 5.63% | 1.74 6.90% | 1.66 -4.40% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.35 -4.68% | 0.30 13.56% | 0.20 6.93% | 0.18 38.59% | 0.38 8.65% | 0.33 11.18% | 0.22 9.45% | 0.20 13.22% | 0.42 9.14% | 0.37 11.86% | 0.22 0.92% |
| Revenue Q2Q % growth | 1.316B 10.31% | 1.343B 8.22% | 1.216B 6.95% | 1.17B 2.27% | 1.356B 3.04% | 1.405B 4.62% | 1.275B 4.85% | 1.223B 4.53% | 1.452B 7.08% | 1.511B 7.54% | 1.361B 6.75% |
| EBITDA Q2Q % growth | 308.38M 9.35% | 270.78M -34.75% | 210.96M -60.42% | 195.2M -72.07% | 330.12M 7.05% | 298.22M 10.13% | 227.52M 7.85% | 205.44M 5.25% | N/A | N/A | N/A |
| EBIT Q2Q % growth | 273.82M 126.30% | 234.31M 175.66% | 175.07M 548.41% | 159.36M 738.74% | 304.43M 11.18% | 261.42M 11.57% | 187.5M 7.10% | 159.18M -0.11% | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
12.11%
EPS Next 5 Year
10.15%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
5.61%
Revenue Next 5 Year
4.86%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
18.81%
EBIT Next 5 Year
13.31%
ELANCO ANIMAL HEALTH INC / ELAN Forecast FAQ
What is the average price target for ELANCO ANIMAL HEALTH INC (ELAN) stock?
22 analysts have analysed ELAN and the average price target is 27.2 USD. This implies a price increase of 13.71% is expected in the next year compared to the current price of 23.92.
Can you provide the upcoming earnings date for ELANCO ANIMAL HEALTH INC?
ELANCO ANIMAL HEALTH INC (ELAN) will report earnings on 2026-05-05, before the market open.
Can you provide the consensus estimates for ELANCO ANIMAL HEALTH INC next earnings?
The consensus EPS estimate for the next earnings of ELANCO ANIMAL HEALTH INC (ELAN) is 0.35 USD and the consensus revenue estimate is 1.32B USD.
What is the expected long term growth rate for ELAN stock?
The expected long term growth rate for ELANCO ANIMAL HEALTH INC (ELAN) is 5.61%.